Drug Profile
Osiris Phleum pratense
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ALK-Abello
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 29 Feb 2012 ALK-Abelló completes a phase II trial in Seasonal allergic rhinitis in Poland (NCT01425788)
- 10 Feb 2012 ALK-Abello completes enrolment in its phase II trial for Seasonal allergic rhinitis in Poland (NCT01425788)
- 29 Aug 2011 Phase-II clinical trials in Seasonal allergic rhinitis in Poland (unspecified route)